Nang Kuang Pharmaceutical Co., Ltd. – FDA 483, Nov 7, 2024

Nang Kuang Pharmaceutical Co. in Tainan City, Taiwan, was cited for significant deficiencies across its drug product manufacturing operations. Observations included inadequate production and process controls, widespread failures in preventing microbiological contamination of sterile products, and a deficient visual inspection program. The inspection also highlighted issues with laboratory controls, environmental monitoring, cleaning and sanitization, and overall Quality Unit oversight, indicating a systemic lack of control over critical GMP processes.